Gene Expression and Diagnosis of Autoimmune Disease

Period of Performance: 07/01/2009 - 06/30/2010


Phase 2 STTR

Recipient Firm

Arthrochip, LLC
Franklin, TN 37069
Principal Investigator


DESCRIPTION (provided by applicant): Autoimmune diseases are thought to arise from abnormalities in innate or adaptive immune responses and most likely have both genetic and environmental components. Diagnosis of autoimmune disease is often difficult, as the symptoms can be relatively nonspecific. Furthermore, no available blood test can accurately exclude the possibility of an autoimmune disease in a subject with such symptoms. At best, a battery of tests and evaluation by a specialist physician over a period of time are required to establish that a patient does in fact have an autoimmune disorder. Initial studies have demonstrated that measurement of gene expression in peripheral blood samples separates subjects with autoimmune disorders from healthy controls with a high degree of accuracy. In the first part of the Phase II period, these observations were extended to demonstrate that expression levels of a less than six genes measured by quantitative real-time PCR can produce similar results. The results show that separation of MS patients from normal controls can be achieved with a high degree of accuracy. Other findings indicate utility of this approach in the diagnosis of patients with rheumatoid arthritis and systemic lupus erythematosus. It is now proposed to extend and expand these results to include larger and more diverse patient groups and to evaluate longitudinal changes. Three specific aims are proposed: Specific Aim I. To better define optimum diagnostic tests for MS, RA, and SLE, we will determine test performance in subjects with other neurologic, other rheumatologic conditions or other chronic diseases. Specific Aim II. We will evaluate test performance in cohorts of individuals from different geographic regions, in individuals with early or incomplete disease, in first-degree unaffected relatives of individuals with MS, RA, or SLE, and in subjects prior to and after initiation of standard therapies for each disease. Specific Aim III. We will design test standards and perform validation studies for our tests as required for FDA approval. We anticipate that the result of these studies will be marketed tests for autoimmune diagnosis that will have a significant impact on patient care. PUBLIC HEALTH RELEVANCE: Autoimmune diseases affect 5% of the population. Unlike many other chronic diseases, these maladies can afflict children and young adults, with long-term health consequences. Diagnosis in early disease stages would be facilitated by the availability of more accurate blood tests, and this is key to timely institution of definitive therapies for prevention of irreversible organ damage.